David A. Reardon, MD Dana-Farber Cancer Institute discusses INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma GBM Interim results.
INO-5401 and INO-9012 in combination with cemiplimab REGN2810 in newly diagnosed glioblastoma GBM Interim results – David A. Reardon, MD Dana-Farber Cancer Institute @DanaFarber #glioblas…
By Editor